Source facts
FDA issued a tentative approval letter for CYCLOPHOSPHAMIDE on 2026-06-05. The source metadata identifies ANDA 219271 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordTA · Tentative Approval Letter
CYCLOPHOSPHAMIDE — FDA Tentative Approval Letter (ANDA 219271)
Issued to HETERO LABS LIMITED. Application meets requirements but marketing is blocked (patent/exclusivity).
Issued
June 5, 2026Application
ANDA 505j • 219271
Product
CYCLOPHOSPHAMIDE
Company
HETERO LABS LIMITED
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for CYCLOPHOSPHAMIDE?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: tentative approval.
- 2Application: ANDA 219271.
- 3Submission: original application.
- 4Sponsor: HETERO LABS LIMITED.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA tentative approval letter (PDF)
Loading document viewer…
Common questions about the CYCLOPHOSPHAMIDE tentative approval letter
Is CYCLOPHOSPHAMIDE FDA approved?
Not for marketing yet. FDA granted tentative approval to ANDA 219271 for CYCLOPHOSPHAMIDE on June 5, 2026, meaning the application meets approval standards but patent or exclusivity protections block final approval. The product cannot be marketed until those conditions resolve and FDA issues final approval.
What is ANDA 219271?
ANDA 219271 is the application under which FDA issued this tentative approval letter for CYCLOPHOSPHAMIDE to HETERO LABS LIMITED. The letter is dated June 5, 2026.
What happens after an FDA tentative approval letter?
The product cannot be marketed yet. Tentative approval means the application meets FDA approval standards, but patent or exclusivity protections block final approval. The sponsor typically requests final approval as the blocking date approaches, and FDA re-verifies that the approval conditions still hold before granting it.